pharmaceutical industry

Most Read

Child with pill

Health By Meghana Keshavan

Tasty and easy to take, a new ADHD drug alarms some psychiatrists

Larry J. Merlo, of CVS Health, made $22,855,374 in total compensation in 2015.

Business By Eric Boodman

Paycheck envy? Check out how much pharma and health care CEOs made last year

Pharma TV Ad

Exclusive By Rebecca Robbins

Drug makers now spend $5 billion a year on advertising. Here’s what that buys.

Aloquin

Pharmalot By Ed Silverman

The curious case of the $9,500 skin gel

Jessica Thomas

Business By Rebecca Robbins

Big Pharma’s big push to get patients to take their meds

Austin Skyline

Business By Sarah C.P. Williams

Could Austin — the ‘Silicon Hills’ of Texas — become the next biotech hub?

Scholar Rock

Business By Elie Dolgin

What’s in a biotech name? How drug startups choose their brand

Lab worker

In the Lab By Eric Boodman

Want to make the big bucks after your PhD? Find a job in industry, study finds

All Coverage

Trump and pharma

Politics By Dylan Scott

The drug industry’s stake in Trumpcare is bigger than you think

Heather Bresch, Doug Throckmorton Mylan

Business By Associated Press

Drug prices don’t budge even after pressure from Congress

advertisement

Pharma needs new Prescription

First Opinion By Dana Goldman and Darius Lakdawalla

Election verdict: Pharma needs a new prescription

Donald Trump

Politics By Dylan Scott

Big Pharma’s big question: Is Trump friend or foe?

Voting California

Politics By Rebecca Robbins

Prop 61: Californians appear to say no to lowering drug costs

Proposition 61

Politics By Rebecca Robbins and Meghana Keshavan

Drug pricing fight in California turns nasty with ads tarring pharma execs as criminals

Proposition 61 - pharmalot

The Pharmalot View By Ed Silverman

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

Richard Burr

Politics By Sheila Kaplan

In a tight race, one of pharma’s favorite senators gets a little help from his friends

antimicrobial resistance

First Opinion By Henry A. Waxman and Bill Corr

Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs

Heather Bresch

Business By Damian Garde

The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes

Donald Trump sign

Politics By Dylan Scott

Donald Trump’s trade talk is making the drug industry uneasy

Dollars

Politics By Sheila Kaplan

5 ways drug makers and the health care industry are shaping campaigns

Brazil Zika microcephaly

In the Lab By Helen Branswell

The race for a Zika vaccine is intense. But it may be missing the most important players

CEO Biotech trading

Don't Miss By Damian Garde

How biotech executives profit from legal insider trades

David Vetter Bubble Boy 1977

Biotech By Damian Garde

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

Pharmacy Benefit Managers

The Pharmalot View By Ed Silverman

The ‘gouge factor’: Big companies want transparency in drug price negotiations

Pfizer Ad

Business By Rebecca Robbins

Why Democratic convention viewers saw so many drug ads

Trump

First Opinion By Charles D. Rosen

Say what you will about Donald Trump. He’s right about drug companies

Mark Cuban

Don't Miss By Dylan Scott

Billionaire businessman Mark Cuban has something to say about drug prices

Acetylcholine receptor

Biotech By Damian Garde

Could a molecular ‘on-off switch for agony’ lead to a safer painkiller?

Hospitals Corridor

Business By Charles Ornstein and Ryann Grochowski Jones — ProPublica

Drug and device makers find receptive audience at for-profit, Southern hospitals

Drug Industry Overstates Patents

The Pharmalot View By Ed Silverman

Drug industry overstates impact of patent reviews on innovation

Brexit

Biotech By Meghana Keshavan and Rebecca Robbins

Post-Brexit, will the European Medicines Agency be homeless?

Supreme Court

Politics By Dylan Scott

Supreme Court’s ruling in patent case a blow to drug industry

Bioprotein

Biotech By Damian Garde

It’s the war of the tchotchkes as drug makers vie for attention at biotech bash